Skip to content

Sortina Pharma

Developing groundbreaking new therapies for recurrent and metastasizing cancers by targeting the sortilin pathway.

Anti-Sortilin treatment – Making a difference for cancer patients

With this new therapy, patients will achieve a reduced recurrence and spreading of cancer and increased survival.

We are developing sortilin antagonistic small molecules, which can reduce the activity and expansion of treatment resistant cancer stem cells which are the leading cause for recurrent and metastatic cancer.

Our mission

Sortina Pharma´s mission is to develop effective first in class pharmacotherapy for cancer patients with or at risk of having recurrent and metastatic cancer.

With this new therapy, patients will achieve a reduced recurrence and spreading of cancer and increased survival. The company is developing sortilin antagonistic small molecules, which can reduce the activity and expansion of treatment resistant cancer stem cells which are the leading cause for recurrent and metastatic cancer.

News and publications

Sortina Pharma AB has appointed Sara Rhost as CEO

Sara has a doctoral degree in immunology from Gothenburg University and has been managing and driving the sortilin-project from research
Read More

Clinical article: Berger et al 2021 BMC Cancer

Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer Read full article
Read More

EIR Ventures investment: Sortina Pharma completes seed-financing to develop breakthrough cancer treatments.

Sortina Pharma AB today announces a financing led by the venture capital fund Eir Ventures and with GU Ventures, to
Read More